Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Alliance Global Partners Initiates Coverage On AcelRx Pharmaceuticals with Buy Rating, Announces Price Target of $4.25

Author: Benzinga Newsdesk | October 02, 2023 07:28am
Alliance Global Partners analyst James Molloy initiates coverage on AcelRx Pharmaceuticals (NASDAQ:ACRX) with a Buy rating and announces Price Target of $4.25.

Posted In: ACRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist